ABSTRACT: A series of gold(III) and palladium (II) (2)]. The complexes have been evaluated for their antiproliferative properties in human ovarian cancer cells sensitive and resistant to cisplatin (A2780S/R), in human breast cancer cells (MCF7) and in a nontumorigenic human embryonic kidney cell line (HEK-293T). The highly cytotoxic trimetallic derivatives M 2 Fe (M = Au, Pd) are more cytotoxic to cancer cells than their corresponding monometallic fragments. Moreover, these complexes were significantly more cytotoxic than cisplatin in the resistant A2780R and the MCF7 cell lines. Studies of the interactions of the trimetallic compounds with DNA and the zinc-finger protein PARP-1 indicate that they exert anticancer effects in vitro based on different mechanisms of actions with respect to cisplatin.
■ INTRODUCTION
Cisplatin and the follow-on drugs carboplatin (paraplatin) and oxaliplatin (eloxatin) are used to treat 40−80% of cancer patients alone or in combination chemotherapy. 1 However, their effectiveness is still hindered by clinical problems, including acquired or intrinsic resistance, a limited spectrum of activity, and high toxicity leading to side effects.
1,2 Promising anticancer activities of a variety of other metal complexes (including organometallic compounds) have been reported in the past 2 decades. 3−8 Recent progress in this field has brought a better understanding of the mode of action for some of these derivatives. 9 In particular, a number of gold compounds have overcome cisplatin resistance to specific cancer cells, 10 which makes them attractive potential therapeutics. In addition, it has been found that DNA is not the primary target for most gold compounds, reinforcing the idea that their mode of action is different with respect to cisplatin. 10, 11 This has prompted the search for alternative biomolecular targets not only for gold but for other non-platinum complexes 10−13 and a revision of the mode of action of anticancer platinum compounds themselves. 14 Thus, multiple biological pathways have been proposed for non-platinum derivatives including the inhibition of mitochondrial enzymes and of the proteasome for gold compounds. 15−17 Recently, some of us also reported on the potent inhibition of the zinc finger protein poly (adenosine diphosphate (ADP) ribose) polymerase 1 (PARP-1) by Au(I) and Au(III) complexes. 18, 19 PARPs are essential proteins involved in cancer resistance to chemotherapies and play a key role in DNA repair by detecting DNA strand breaks and catalyzing poly(ADP-ribosylation). 20, 21 Within this frame, there has been a growing interest in heterometallic complexes as potential anticancer agents. 22−26 The hypothesis is that the incorporation of two different cytotoxic metals in the same molecule may improve their activity as antitumor agents because of interaction of the different metals with multiple biological targets or by the improved chemicophysical properties of the resulting heterometallic compound. The anticancer properties of certain molecules may be increased by the introduction of the organometallic ferrocene motif in the framework because of its low toxicity, high lipophilicity, and unique electrochemical behavior. 27−29 Thus, several examples of heterometallic complexes incorporating ferrocene and a second cytotoxic metal (Au(I), 30−36 Pt(II), 30,37−42 Pd(II), 40,43−45 Ru(II), 46−50 Rh(I), 40, 51, 52 Ir(I), 40 and Cu(I) 53, 54 ) appeared in the literature.
In most cases the antiproliferative properties of the resulting compounds improved with respect of that of the corresponding ferrocene-based ligand, although synergistic effects of the two different metals were evaluated only in one case. 50 Some of us have reported that nontoxic iminophosphorane or iminophosphane (IM) compounds serve as stabilizing (C,Nor N,N) chelating ligands in the preparation of anticancer organometallic and coordination d 8 metal complexes. 55−58 Organogold(III) complexes containing iminophosphorane (C,N-IM) ligands of the type PPh 3 NPh displayed a high cytotoxicity in vitro against human ovarian cancer and leukemia cell lines (in some cases with IC 50 values in the nanomolar range) 55, 56 while being less toxic to normal T-lymphocytes by a non-cisplatin mode of action (involving mitochondrial production of reactive oxygen species). 56 More recently, we have reported on the cytotoxicity of coordination and organometallic Pt(II) and Pd(II) complexes with water-soluble iminophosphorane ligands. 57, 58 Interestingly, we observed that some of these Pt and Pd compounds were more cytotoxic than cisplatin to leukemia cell lines (both T-Jurkat and cisplatinresistant Jurkat sh-Bak) by a mode of action different from that of cisplatin. 57, 58 Within this frame, we aimed to explore the biological properties of related IM complexes containing Au(III) and Pd(II) centers incorporating the ferrocene motif, and we report here on the synthesis of new iminophosphorane ligands derived from ferrocenylphosphanes [{Cp-P(Ph 2 )N-Ph} 2 The compounds were also tested for their possible interactions with plasmid (pBR322) DNA used as a model nucleic acid and for their reactivity with the transport protein serum albumin (HSA). Moreover, the most promising compounds out of the cytotoxicity screening, the trimetallic M 2 Fe complexes, were tested for PARP-1 inhibition directly on the purified protein. The obtained results have been discussed in relation to the compounds' possible mechanisms of anticancer action.
■ RESULTS AND DISCUSSION 1. Synthesis and Characterization. Ligands 1 and 2 derived from 1,1′-bis-diphenylphosphinoferrocene (DPPF) can be conveniently prepared in moderate yields by reaction of commercial DPPF and phenylazide (1) or 2-methylpyridineazide (2) by the Staundinger 59 method (Scheme 1). Ligand 3 can be prepared in an analogous way in high yields by reacting diphenylphosphinoferrocene (MPPF) 60 and methylpyridineazide. The ligands hydrolyze quickly to amines and the corresponding phosphane oxides at air in solution or as solids due to moisture. They can be conveniently stored in dry glassware under nitrogen for months.
Ligands 2 and 3 serve as excellent precursors to bimetallic or trimetallic derivatives incorporating Au(III) and Pd(II) centers (Scheme 2). The reaction of ligand 1 to obtain a dinuclear derivative Fe−Au with the Au coordinated to the 2N of the iminophosphorane fragments did not proceed as expected. The incorporation of one or two pyridyl groups in the iminophosphorane ligands 2 and 3 allows for the preparation of coordination dimetallic (7, 8) (4, 5) or days (6, 7, 11) or several hours (8, 10) . The most stable complexes are the protonated ligand (4), the trimetallic complexes M 2 Fe (M = Au 5; M = Pd 6), and gold dimetallic (7) species. All the palladium complexes and the gold (10) with the Ph 3 PN-CH 2 -2-NC 5 H 4 (IMPPh 3 ) ligand (9) decompose to cyclometalled species (in the case of ligand 9 the metalation occurs at the aryl group of the PPh 3 phosphane, while in the case of the ferrocenylphosphane derivatives the metalation occurs both at the aryl ring of the PPh 2 fragment and at the cyclopentadienyl of the ferrocene fragment). The stability of 10 in DMSO−H 2 O is very poor, and therefore, the incorporation of ferrocene fragments to the iminophosphorane ligand was advantageous to improve the stability of the related gold complexes. In all cases the 
90.08 (7) Cl ( In order to further characterize the stability of the compounds, in physiological-type conditions, we recorded the UV−visible spectra of the metal complexes in PBS solution over time. Representative spectra of compounds 5 and 10 are reported in Figure S22 in the Supporting Information. As can be seen in the case of 5, the compound's absorption spectrum is almost unaltered even after 12 h of incubation at room temperature, whereas the absorption rapidly decreases with time in the case of the mononuclear gold compound 10.
The structures of compounds 8 and 11 have also been determined by X-ray diffraction analysis (Figure 2 ). Selected bond lengths and angles for both compounds are collected in Table 1 .
The geometry about the Pd(II) centers is pseudo-squareplanar with the N(2)−Pd (1) 64 The distances of PN are shorter than in compounds that incorporate a carbonyl group bonded to the iminic nitrogen (because of a smaller delocalized charge density compared to the CO group). 57, 58 Because of the difficulties of obtaining experimental crystal structures for the gold and palladium complexes 5−7, we used computational DFT methods to verify if the suggested molecular structures would be favorable. The initial geometry for the models was taken from the crystal structure of 8 and 11 or modeled using resembling structures obtained from the Cambridge Crystallographic Data Base. Figure 3 shows the energetically most favorable structures for the complexes; the freely optimized ligand structures can be found in the Supporting Information ( Figure S1 ).
In all complexes, the coordination of the metal atoms (Au, Pd) was slightly twisted square planar. The most important difference between the freely optimized ligand structures and corresponding complexes was the torsional behavior of the nitrogen atoms and also of the ferrocene rings. In separately optimized ligands, the minimum energy conformation of the N−C−C−N(py) torsion was near 180°, while obviously the complexation of the nitrogens resulted in cis-confomation. Also, for the doubly substituted free ligand 2 the ferrocene rings were optimized in staggered conformation instead of the effectively eclipsed one obtained for the metallic complexes Fe−Au 2 5 and Fe−Pd 2 6 (see Figure 3 and Figure S1 ). For these compounds the energetically most stable structures were obtained when the substituents were located at the 1 and 3′ carbon atoms of the ferrocene rings.
We tested the effect of the initial substitution sites (1,2′) also for compounds 5 and 6. In the case of the cationic Fe−Au 2 complex 5, the ferrocene rings turned into a staggered conformation resulting effectively again into 1,3′ substitution. In the case of the Fe−Pd 2 complex 6, the optimization resulted in a more "closed" structure, which had only a slightly higher total energy. It could be concluded therefore that both structures are feasible for the Fe−Pd 2 compound 6 (see Figure  S2 in the Supporting Information). Table 2 lists the selected bond distances and electronic properties for the compounds. The calculated IR spectra are also compared for selected stretching modes in Table 2 . The trend in the shifts for the ν(M−Cl) values is clear: the Au complexes 5, 7, and 10 exhibited larger wavenumbers for the asymmetric and symmetric M−Cl stretch than the corresponding palladium complexes 6, 8, and 11 (see more details in the Supporting Information Figures S3−S8 ).
This correlates very well in the optimized M−Cl distances, since the Au−Cl distances were about 0.03 Å shorter than the Pd−Cl distances. The ν(PN) values in the complexes were found to be very similar. The same trends are also seen in the experimental frequencies, even though the computational absolute values are slightly overestimated, which is typical for the applied DFT method.
The formation energies of the compounds were also investigated (see Table 2 and Supporting Information for details), and it was found that all the studied complexes are readily formed. The larger HOMO−LUMO gap, on the other hand, indicates that palladium complexes 6 and 8 are more stable and thus less reactive than the gold analogues 5 and 7. This is in accordance with our previous observation for gold(III) coordination compounds containing iminophosphor- a Gibbs free energies refer to formation reactions, where the corresponding metal ions react with chloride ions and the corresponding free ligands. GAP is the energy difference between the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO). b IR spectra were simulated in aqueous solvent (experimental values obtained from Nujol mulls between polyethylene sheets). For the doubly substituted complexes, the reaction energies were scaled per metal atom.
ane ligands. 56 Interestingly, the gold complex 10 does not show a similar reduction in the HOMO−LUMO gap, indicating that the ferrocene motif can increase the reactivity of the compounds and that the ferrocene moiety has a larger effect on gold complexes than on palladium ones. Experimentally 10 is the most unstable compound of the series most likely due to a cyclometalation process in DMSO. However, this cyclometalation process was not in the scope of our computational studies, and therefore, the energetics could not reveal this particular detail of the relative stability.
2. Biological Activity. Figure 1 ) were assayed by monitoring their ability to inhibit cell growth using the MTT assay (see Experimental Section). Cytotoxic activity of the compounds was determined as described in the Experimental Section in the human ovarian cancer A2780 cell line, and its cisplatin resistant variant (A2780cisR), as well as in the human breast cancer cell line MCF7, in comparison to cisplatin. The results are summarized in Table 3 . In general the ferrocene-based ligands are poorly cytotoxic in all tested cell lines, and this may be caused by their poor solubility in aqueous solution. Interestingly, ligands 1−3 incorporating the ferrocenylphosphanes are considerably more cytotoxic than the purely organic ligand 9 containing triphenylphosphane. This is in agreement with the enhanced antripoliferative properties for a vast majority of derivatives in which an aryl group is substituted by the ferrocene motif. 20, 21 Concerning the dimetallic complexes derived from ligand 3 (based on MPPF), the Pd(II) derivative 8 is markedly more cytotoxic than 3 and the Au(III) derivative 7. Moreover, such dimetallic complexes are less active than their monometallic IM-PPh 3 analogues 10 (Au) and 11 (Pd) on the ovarian cancer cell lines A2780S/R. The reduced effect of the gold compound 10 may also be due to its reduced stability in aqueous medium as explained in the previous section. Concerning the trimetallic M 2 Fe (M = Au 5, M = Pd 6) compounds with ligand 2 (based on DPPF), these complexes exhibit important cytotoxic effects in the low micromolar range in all the studied cell lines. Notably, they are also significantly more cytotoxic than cisplatin toward the resistant A2780R and MCF7 cell lines. The trimetallic compounds were also significantly more cytotoxic than ligands 1 and 2 and more effective than the monometallic Au and Pd derivatives 10 and 11. In order to assess the selectivity of compounds for cancerous cells with respect to normal cell lines, the most cytotoxic heterometallic compounds were also screened for their antiproliferative effects on the nontumorigenic human embryonic kidney cells HEK293T. In most cases the cytotoxicity is comparable for the cancerous and normal cell lines.
In the case of monometallic Pd only, compound 11 is markedly (∼7.5-fold) more toxic on the cancerous cell lines (IC 50 of 6−7 μM) than on the noncancerous HEK293T cells (IC 50 of ∼45 μM). Finally, compound 4 was among the most cytotoxic in all the tested cell lines including the HEK293T cells, and this may be attributed to the presence of the AuCl 4 − anion in the compound with a highly oxidative character leading to marked and unselective cell death. Such type of goldbased ionic compound being highly toxic in the nontumorigenic cell line will certainly not be selected for further biological screening.
2.2. Reactivity with Biomolecules. 2.2.1. Interactions with Plasmid DNA. Since DNA replication is a key event for cell division, it is among the critically important targets in cancer chemotherapy. Most cytotoxic platinum drugs form strong covalent bonds with the DNA bases. 66 However, a variety of platinum compounds act as DNA intercalators upon coordination to the appropriate ancillary ligands. 67 There are also reports on palladium derivatives interacting with DNA in covalent 68,69 and noncovalent fashion. 70, 71 Conversely, most gold-based compounds do not display a strong interaction with DNA. 10, 11 Thus, we performed agarose gel electrophoresis studies to unravel the effects of the new heterometallic compounds 5−8, 10, and 11 on plasmid (pBR322) DNA (Figure 4 ). This plasmid has two main forms: OC (open circular or relaxed form, form II) and CCC (covalently closed or supercoiled form, form I). Changes in electrophoretic mobility of both forms are usually taken as evidence of metal−DNA binding. Generally, the larger the retardation of supercoiled DNA (CCC, form I), the greater is the DNA unwinding produced by the drug. 72 Binding of cisplatin to plasmid DNA, for instance, results in a decrease in mobility of the CCC form and an increase in mobility of the OC form (see lanes a−d for cisplatin in Figure 4) .
Treatment with increasing amounts of Au(III) compounds with IM ligands containing ferrocene 5 and 7 and the Au(III) compound with an IM-PPh 3 ligand 10 does not affect the mobility of the faster-running supercoiled form (form I) even at the highest molar ratios (lane d). This is also in accordance with previously reported results on organogold(III) compounds containing iminophosphorane ligands that did not interact with DNA. 55 Conversely, the Pd(II) compounds with IM ligands containing ferrocene 8 or triphenylphosphine 11 have a behavior similar to that of a coordination iminophosphorane palladium complex described by us [PdCl 2 (TPAN-C(O)-2-NC 5 H 4 )]. 56 In fact, these compounds significantly modify the electrophoretic mobility and the retardation of the fasterrunning supercoiled form (form I or CCC), and an increased electrophoretic mobility of form II (OC) was clearly observed for 6, 8, and 11 at ratios lower than those for cisplatin. Moreover, the Pd complexes 8 and 11 are able to induce a coalescence of the two plasmid forms, an effect that has already been described for cisplatin, but at higher drug/DNAbp ratios. 73 The presence of a coalescence point indicates a strong unwinding of the pBR322 plasmid DNA for compounds 8 and 11. The trimetallic Fe−Pd 2 compound 6 (with ligand 2 derived from DPPF) also shows a coalescence point at the lowest metal/DNA ratio (0.25, line a), most likely followed by a change of conformation of plasmid DNA from negative supercoil to positive supercoil at the highest metal compound/DNAbp ratios.
Overall, our results indicate interactions of the new iminophosphorane palladium complexes, mono-and heterometallic (Fe−Pd), with DNA that are stronger than that observed for cisplatin.
2.2.2. Inhibition of PARP-1. As previously mentioned, the zinc finger protein PARP-1 has been recently identified as a possible taget for Au(III) complexes in vitro. 18, 19 Information on the reactivity of the gold complexes with the PARP-1 zincfinger domain was also obtained by high-resolution mass spectrometry, and an excellent correlation between PARP-1 inhibition in protein extracts and the ability of the complexes to bind to the zinc finger motif (in competition with zinc) was established. 18 Thus, in order to further investigate the mechanisms of action of the new heteronuclear complexes, we tested the mononuclear compounds 5 and 6 for their PARP-1 inhibition properties in vitro as reported in the Experimental Section. The obtained preliminary results showed that the trinuclear Au−Fe compound 5 is a potent PARP-1 inhibitor with IC 50 = 1 ± 0.5 μM, while the trinuclear Pd−Fe analogue 6 is much less effective with IC 50 = 17 ± 0.8 μM.
2.2.3. Interactions with HSA. Human serum albumin (HSA) is the most abundant carrier protein in plasma and is able to bind a variety of substrates including metal cations, hormones, and most therapeutic drugs. It has been demonstrated that the distribution, the free concentration, and the metabolism of various drugs can be significantly altered as a result of their binding to the protein. 74 HSA possesses three fluorophores, these being tryptophan (Trp), tyrosine (Tyr), and phenylalanine (Phe) residues, with Trp214 being the major contributor to the intrinsic fluorescence of HSA. This Trp fluorescence is sensitive to the environment and binding of substrates, as well as changes in conformation that can result in quenching (either dynamic or static). Thus, the fluorescence spectra of HSA in the presence of increasing amounts of the representative compounds 5, 7, and 8 and cisplatin were recorded in the range of 300−450 nm upon excitation of the tryptophan residue at 295 nm ( Figure 5 ). The compounds caused a concentration dependent quenching of fluorescence without changing the emission maximum or shape of the peaks (5, 7, 8) , as seen in Figure 5A for compound 7. All these data indicate an interaction of the heterometallic compounds with HSA. The fluorescence data were analyzed by the Stern− Volmer equation. While a linear Stern−Volmer plot is indicative of a single quenching mechanism, either dynamic or static, the positive deviation observed in the plots of F 0 /F versus [Q] of our compounds ( Figure 5) suggests the presence of different binding sites in the protein. 75 Of note, a similar behavior was observed in the case of coordination iminophosphorane complexes of d 8 metals for which we also reported a concentration dependent fluorescence quenching. 57, 58 In this graph higher quenching by the iminophosphorane complexes was observed compared to that of cisplatin under the chosen conditions, most likely due to the faster reactivity of our compounds with HSA compared to cisplatin.
In the case of [MCl 2 (TPAN-C(O)-2-NC 5 H 4 )] (M = Pd, Pt), isothermal titration calorimetry (ITC) 57 showed two different binding interactions that explained the lack of linearity observed in the fluorescence quenching studies, as the Stern− Volmer method assumes all binding sites to be equivalent. We believe that a similar reactivity takes place for the iminophosphorane compounds described here. 
■ CONCLUSIONS
We have prepared a series of coordination iminophosphorane complexes of gold(III) and palladium(II) derived from ferrocenylphosphanes. The new compounds are markedly more stable than the ferrocenylphosphane ligands in DMSO or aqueous solution and more stable than their monometallic analogues derived from PPh 3 [(AuCl 2 (Ph 3 PN-CH 2 -2-NC 5 H 4 )]ClO 4 10 and [PdCl 2 {N-CH 2 -2-NC 5 H 4 }] 11. The most stable trimetallic M 2 Fe (M = Au, Pd) derivatives (5 and 6) exhibit important cytotoxic effects in the low micromolar range in all the cancer cells studied and are more cytotoxic than their corresponding monometallic fragments (ligand 2 containing ferrocene and monometallic analogues 10 and 11), also indicating a possible synergistic antiproliferative effect of the two different metals. Importantly, these complexes were significantly more cytotoxic than cisplatin in the resistant A2780R and MCF7 cell lines, supporting the idea of different mechanisms of action than cisplatin.
It is worth mentioning that heterometallic trinuclear complexes have already been described by some of us to be more stable than their mononuclear and dinuclear precursors, including gold−titanium complexes. 24, 25 Moreover, improved biological properties of multinuclear complexes with respect to mononuclear compounds have been reported, 26 which could be related to favorable modulation of the stability, solubility, and/ or lipophilicity of the organometallic scaffolds. Therefore, the results described herein support the idea that there is an advantage in synthesizing heteronuclear complexes as anticancer agents.
When the reactivity of the new heteronuclear complexes was tested with plasmid DNA, the Pd(II) derivatives showed strong interactions with nucleic acids while the Au(III) analogues were practically ineffective. Instead, the Au(III) complexes were good inhibitors of the zinc-finger protein PARP-1, a possible target enzyme for anticancer metal compounds, while the Pd(II) complexes were markedly less potent. In general, although further studies are necessary to validate the mechanisms of biological action of this new series of heteronuclear metal compounds, our results support the idea of different reactivity of the complexes with the investigated biomolecules depending on the metal ion and not only on the ligand set.
■ EXPERIMENTAL SECTION
All manipulations involving air-free syntheses were performed using standard Schlenk-line techniques under a nitrogen atmosphere or in a glovebox MBraun MOD system. Solvents were purified by use of a PureSolv purification unit from Innovative Technology, Inc. ) were recorded on a Nicolet 6700 FT-IR spectrophotometer from Nujol mulls between polyethylene sheets. Mass spectra (ESI) were performed on an Agilent analyzer or a Bruker analyzer. Conductivity was measured in an OAKTON pH/conductivity meter in CH 3 CN solutions (10 −3 M). Xray collection was performed at room temperature on a Kappa CCD diffractometer using graphite monochromated Mo Kα radiation (λ = 0.710 73 Å). Electrophoresis experiments were carried out in a BioRad Mini subcell GT horizontal electrophoresis system connected to a Bio-Rad Power Pac 300 power supply. Photographs of the gels were taken with an Alpha Innotech FluorChem 8900 camera. Fluorescence intensity measurements were carried out on a PTI QM-4/206 SE spectrofluorometer (PTI, Birmingham, NJ) with right angle detection of fluorescence using a 1 cm path length quartz cuvette. Circular dichroism spectra were recorded using a Chirascan CD spectrometer equipped with a thermostated cuvette holder. UV−visible spectra have been recorded using a on a Perkin-Elmer Lambda 20 Bio spectrophotometer.
Synthesis. [{Cp-P(Ph 2 )N-Ph} 2 Fe] (1). A solution of DPPF (0.554 g, 1.0 mmol) in 15 mL of degassed CH 2 Cl 2 and a solution of phenylazide (0.238 g, 2.0 mmol) in 5 mL of degassed CH 2 Cl 2 were mixed and refluxed for 3 h and 40 min under nitrogen. After the mixture was cooled to room temperature, the solvent was evaporated to ∼2 mL. By addition of 6 mL of dry Et 2 O and 4 mL of dry n-hexane, a precipitate formed which was separated by filtration under nitrogen. [{(Cp-P(Ph 2 )N-CH 2 -2-NC 5 H 4 )AuCl 2 }Fe(Cp)]ClO 4 (7) . To a solution of K[AuCl 4 ] (0.113 g, 0.3 mmol) in CH 3 CN (10 mL) was added AgClO 4 (0.068 g, 0.33 mmol). The resulting yellow reaction mixture was stirred at room temperature (protected from the light) during 30 min and subsequently filtered through a Celite pad (to remove the AgCl formed). To the resulting yellow solution was added 3 (0.071 g, 0.15 mmol). KClO 4 precipitated immediately in the reaction medium, and after 1 h stirring at room temperature the reaction mixture was filtered through a Celite pad. The solvent was reduced to ∼2 mL, and a precipitate was obtained by addition of [ X-ray Crystallography. Single crystals of 8 and 11 (see details in Table S1 in Supporting Information) were mounted on a glass fiber in a random orientation. Data collection was performed at room temperature on a Kappa CCD diffractometer using graphite monochromated Mo Kα radiation (λ = 0.710 73 Å). Space group assignments were based on systematic absences, E statistics, and successful refinement of the structures. The structures were solved by direct methods with the aid of successive difference Fourier maps and were refined using the SHELXTL 6.1 software package. All nonhydrogen atoms were refined anisotropically. Hydrogen atoms were assigned to ideal positions and refined using a riding model. Details of the crystallographic data are given in Table S1 Computational Studies. All models were fully optimized with the Gaussian 09 program package 76 at the DFT level of theory. A hybrid density functional PBE0 77 was utilized together with the quasirelativistic effective core potential basis set def2-TZVPPD 78 for metal atoms (Au, Pd, Fe) and with the standard all-electron basis sets 6-31G(d) for all other atoms. Solvent effects of the aqueous solvent were calculated with the conductor-like polarized continuum model (CPCM) 79 for the gas phase optimized structures. Frequency analysis was done without scaling.
Cell Culture and Inhibition of Cell Growth. The human breast cancer cell line MCF7 and human ovarian cancer cell lines A2780 and A2780cisR (obtained from the European Centre of Cell Cultures ECACC, Salisbury, U.K.) were cultured respectively in DMEM (Dulbecco's modified Eagle Mmedium) and RPMI containing GlutaMaxI supplemented with 10% FBS and 1% penicillin/ streptomycin (all from Invitrogen) at 37°C in a humidified atmosphere of 95% of air and 5% CO 2 (Heraeus, Germany). Nontumoral human embryonic kidney cells HEK293 were kindly provided by Dr. Maria Pia Rigobello (CNRS, Padova, Italy) and were cultivated in DMEM medium, added with GlutaMaxI (containing 10% FBS and 1% penicillin/streptomycin (all from Invitrogen), and incubated at 37°C and 5% CO 2 . For evaluation of growth inhibition, cells were seeded in 96-well plates (Costar, Integra Biosciences, Cambridge, MA) and grown for 24 h in complete medium. Solutions of the compounds were prepared by diluting a freshly prepared stock solution (in DMSO) of the corresponding compound in aqueous medium (RPMI or DMEM for the A2780 and A2780cisR or MCF7 and HEK293, respectively). Afterward, the intermediate dilutions of the compounds were added to the wells (100 μL) to obtain a final concentration ranging from 0 to 150 μM, and the cells were incubated for 72 h. DMSO at comparable concentrations did not show any effects on cell cytotoxicity. Following 72 h of drug exposure, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to the cells at a final concentration of 0.25 mg mL −1 and incubated for 2 h. Then the culture medium was removed and the violet formazan (artificial chromogenic precipitate of the reduction of tetrazolium salts by dehydrogenases and reductases) dissolved in DMSO. The optical density of each well (96-well plates) was quantified three times in tetraplicate at 540 nm using a multiwell plate reader, and the percentage of surviving cells was calculated from the ratio of absorbance of treated to untreated cells. The IC 50 value was calculated as the concentration reducing the proliferation of the cells by 50% and is presented as a mean (±SE) of at least three independent experiments. PARP-1 Activity Determinations. PARP-1 activity was determined using Trevigen's HT universal colorimetric PARP assay. This assay measures the incorporation of biotinylated poly (ADP-ribose) polymerase onto histone proteins in a 96 microtiter strip well format. Recombinant human PARP-1 (high specific activity, purified from E.coli containing recombinant plasmid harboring the human PARP gene, supplied with the assay kit) was used as the enzyme source. 3-Aminobenzamide (3-AB), provided in the kit, was used as control inhibitor. Two controls were always performed in parallel: a positive activity control for PARP-1 without inhibitors, which provided the 100% activity reference point, and a negative control without PARP-1 to determine background absorbance. PARP-1 was incubated with different concentrations of compounds for 1 h at room temperature prior to deposition on the plate wells. The final reaction mixture (50 μL) was treated with TACS-Sapphire, a horseradish peroxidase colorimetric substrate, and incubated in the dark for 30 min. Absorbance was read at 630 nm after 30 min. The data correspond to the mean of at least three experiments performed in triplicate ± SD.
Interaction of Compounds 5−8, 10, 11 and Cisplatin with Plasmid (pBR322) DNA by Electrophoresis (Mobility Shift Assay). The 10 μL aliquots of pBR322 plasmid DNA (20 μg/mL) in buffer (5 mM Tris/HCl, 50 mM NaClO 4 , pH 7.39) were incubated with different concentrations of the compounds (5−8, 10, 11) (in the range 0.25 and 4.0 metal complex/DNAbp) at 37°C for 20 h in the dark. Samples of free DNA and cisplatin−DNA were prepared as controls. After the incubation period, the samples were loaded onto the 1% agarose gel. The samples were separated by electrophoresis for 1.5 h at 80 V in Tris-acetate/EDTA buffer (TAE). Afterward, the gel was stained for 30 min with a solution of GelRed nucleic acid stain.
Interaction of Compounds 5, 7 and 8 with HSA by Fluorescence Spectroscopy. A solution of each compound (8 mM) in DMSO was prepared, and 10 aliquots of 2.5 μL were added successively to a solution of HSA (10 μM) in phosphate buffer (pH 7.4) to achieve final metal complex concentrations in the range 10− 100 μM. The excitation wavelength was set to 295 nm, and the emission spectra of HSA samples were recorded at room temperature in the range 300−450 nm. The fluorescence intensities of the metal compounds 5, 7, and 8, the buffer, and the DMSO are negligible under these conditions. The fluorescence was measured 240 s after each addition of compound solution. The data were analyzed using the classical Stern−Volmer equation 
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